Press Release Jan2012 Dga Grant Pherecydes Eng Bmsystems
Pherecydes Pharma secures DGA funding forevaluating the use of bacteriophagesagainst infected, antibiotic resistant burnsThe French Government Defence procurement agency invests €900,000towards Pherecydes Pharma managed €1.2-million project,involving several university laboratories
Published on: Mar 4, 2016
Transcripts - Press Release Jan2012 Dga Grant Pherecydes Eng Bmsystems
Pherecydes Pharma secures DGA funding for evaluating the use of bacteriophages against infected, antibiotic resistant burns The French Government Defence procurement agency invests €900,000 towards Pherecydes Pharma managed €1.2-million project, involving several university laboratoriesParis, France – January 18, 2012 – Pherecydes Pharma, a biotechnology companyspecialized in the research and development of lytic bacteriophages for both therapeutic anddiagnostic purposes, today announces that it has received funding of €900,000 fromFrance’s General Directorate for Armaments (Direction Générale de l’Armement - DGA) topart-finance PACOBURNS project. This project is set up to explore the possibility of usingbacteriophages to combat bacterial infections that are resistant to antibiotics, especially skininfections.The funds invested by the DGA fall within the framework of its RAPID program. The schemesupports dual innovation by small and medium-sized companies through providing financialassistance for projects that have great technological and commercial potential, areinnovative in terms of industrial research, and have both military and civilian applications.The Institute of Genetics and Microbiology of the University of Paris XI and the ArmedForces Institute of Biomedical Research (Institut de Recherche Biomédicale des Armées -IRBA) are also involved in this project.The PACOBURNS project aims to explore the role and potential of bacteriophages as ameans of combating bacterial infections, especially against germs that are multi-resistant toantibiotics. It also involves promoting the use of phages as a credible alternative toantibiotics.Using relevant animal models, PACOBURNS will make it possible to evaluate the therapeuticefficacy, safety and pharmacodynamics of two cocktails of bacteriophages. The first one isdesigned for infections caused by Escherichia coli type bacteria, and the second forinfections caused by Pseudomonas aeruginosa species, and more specifically for treatingopen burn wounds infected by these resistant germs. Trials on humans are scheduled tobegin early-mid 2013.The project is targeting a market where antibiotics are becoming less effective. Resistanceto antibiotics has become a major public health problem; at least 25,000 people die inEurope each year as a result of antibiotic-resistant infections.This challenge is also of concern to the armed forces’ health services, which areencountering increasing resistance to antibiotics in both military personnel and civilians,especially when it comes to the treatment of serious burns, as well as respiratory tractinfections.In the current state of pharmaceutical research, no new antibiotic is likely to reach themarket over the next eight to ten years. It is against this background of therapeuticbottleneck that phagotherapy is emerging as a realistic alternative to current treatmentsthat are losing their effectiveness.“Despite optimizing the use of antibiotics, situations of therapeutic impasse are increasinglycommon in the case of multi-resistant bacteria,” explained Dr. Patrick Jault, head of theBurns Treatment Center of Percy military hospital near Paris and the future coordinator of
the multicenter trial in man. “It is thus essential to explore new avenues, andbacteriophages are one of the most promising. It is now crucial to evaluate their merits andtheir therapeutic potential in humans.”Pherecydes Pharma is going to bring to the PACOBURNS project its expertise in the isolationand purification of lytic bacteriophages capable of destroying certain bacterial strains,including strains that have become resistant to antibiotics. Thanks to its large collections ofbacteriophages (including the world’s biggest collection of bacteriophages against E. coli),the company will concoct the two cocktails to be used in this project.Pherecydes Pharma will also be responsible for the bioproduction of phages in GLP (GoodLaboratory Practice) conditions, the finalization of the liquid formulas, and the initial in vitrotests. Preliminary tests conducted in rats demonstrated a complete absence of toxicity,perfect tolerability and 100% efficacy.“Pherecydes Pharma’s participation in this innovative project is a major recognition not onlyof its technology but also of the therapeutic potential of its products,” said the chairman ofPherecydes Pharma, Jérôme Gabard. “Bacteriophages are a solution of the future forproblems associated with bacterial resistance, and this project should help establishphagotherapy as both an alternative and a complement to antibiotic-based treatments.”PACOBURNS will enable Pherecydes Pharma to speed up the development of its leadingtherapeutic products, in particular through facilitating their future evaluation in man by themajor burns units of military and civilian hospitals. The company then intends to extend thetopical application of its cocktails to other skin pathologies (such as varicose ulcers), afterthat to test new products administered by aerosol and lastly by the internal route.As for the other partners in the project, the Institute of Genetics and Microbiology of theUniversity of Paris XI will be responsible for electronic microscopy and bacteriophagesequencing, while IRBA will provide a mouse model adapted to the initial preclinicalevaluations.ACE Management, the majority shareholder in Pherecydes Pharma, has close ties withdefence companies along with defense-related projects and is supporting this promisinginnovative project. The second shareholder BioModeling Systems, has innovations that havehelped Pherecydes Pharma participate in the PACOBURNS project.About Pherecydes PharmaPherecydes Pharma SA specializes in the research and development of lytic bacteriophages(or phages) for both therapeutic and diagnostic applications. The company providesinnovative and adaptable solutions to combat multi-resistant bacteria, through developingmixtures of natural phages and their accelerated in vitro evolution. Pherecydes Pharma isthe only company currently that has been able to harness this evolution technology, allowinga head start on any given bacterium.Due to the unique knowledge of the company in the characterization and rapid isolation ofnatural lytic phages, Pherecydes Pharma has developed a large bank of bacteriophagemixtures for combating infections that are resistant to antibiotics, which have steadilyincreased in number since the 1980s. In particular, it possesses the world’s largestcollection of phages against Escherichia coli and is also working on Pseudomonas andStaphylococci, three bacteria that alone represent over 50% of known infections inindustrialized countries.Pherecydes Pharma’s proprietary technology is protected by three patents. The mostimportant patent, TAPE®, targets the accelerated optimization of protein. The company isputting in place a standardized and certified industrial-scale phage development platformand plans to embark on clinical trials of its first products before the middle of 2013. Besidesthe human health sector, Pherecydes Pharma’s technologies are also applicable in the areasof nanotechnology and biodefense.
Pherecydes Pharma is based at the Biocitech life sciences technology park near Paris andhas been operational since the end of 2007. It currently employs six people and plans todouble its workforce in 2012. It has raised over 2.3 million euros from private investors andOSEO, France’s state innovation fund. The company collaborates with academic institutionssuch as the University of Paris-Sud, the French National Scientific Research Center (CNRS),and various university hospitals, as well as with military partners, such as IRBA, the militaryhospitals of Percy and Bégin in France and Queen Astrid in Belgium, and with thePHAGESPOIRS patients’ association (which promotes the use of phage-based therapeutics).For further information, go to: http://www.pherecydes-pharma.com For further information, please contact: Andrew Lloyd and Associates Andrew Lloyd / Neil Hunter email@example.com / firstname.lastname@example.org Tel : +44 1273 675100